PROGENRA, INC.

Basic Information

271A GREAT VALLEY PKWY
271A GREAT VALLEY PKWY
MALVERN, PA, 19355-

Company Profile

n/a

Additional Details

Field Value
DUNS: 190641816
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Ubiquitin pathway inhibitors for treatment of asthma

    Amount: $222,380.00

    DESCRIPTION (provided by applicant): Asthma is a chronic disease with considerable morbidity and no cures. Symptomatic treatment is efficacious but produces significant adverse effects. Thus, improved ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Chemical optimization of a novel class of USP7 inhibitor for cancer treatment

    Amount: $224,974.00

    DESCRIPTION (provided by applicant): Many regulatory proteins are themselves tightly controlled by ubiquitin conjugating and deconjugating enzymes, whose dysfunctional forms are implicated in numerous ...

    SBIR Phase I 2014 Department of Health and Human Services
  3. Ubiquitin based therapy of aggressive cancer cell populations

    Amount: $224,768.00

    DESCRIPTION (provided by applicant): The degradation of most cellular proteins is regulated by coordinated addition and removal of ubiquitin by families of ubiquitin E3 ligases and deubiquitylating en ...

    SBIR Phase I 2014 Department of Health and Human Services
  4. Development of selective substrate based inhibitors of ubiquitin isopeptidases

    Amount: $224,379.00

    DESCRIPTION (provided by applicant): The FDA approval of the proteasome inhibitor bortezomib/VELCADE(r) for the treatment of multiple myeloma and other hematological malignancies demonstrates that the ...

    SBIR Phase I 2014 Department of Health and Human Services
  5. Novel treatment for Huntington???s Disease

    Amount: $224,512.00

    DESCRIPTION (provided by applicant): Because of their degeneracy and selective involvement in most cellular pathways, ubiquitin conjugating and deconjugating enzymes are being explored as therapeutic ...

    SBIR Phase I 2014 Department of Health and Human Services
  6. Selective inhibitors of ubiquitin E3 ligase to treat high cholesterol

    Amount: $1,223,326.00

    DESCRIPTION (provided by applicant): Hypercholesterolemia is a major risk factor in cardiovascular diseases; it is estimated that gt35 million individuals in the U.S. (or one-sixth of the adult popula ...

    SBIR Phase II 2014 Department of Health and Human Services
  7. Ubiquitin E3 ligase detection by fluorescence resonance transfer

    Amount: $1,334,521.00

    The ubiquitin-proteasome pathway degrades ~80-90% of cellular proteins and is of great interest as a source of new therapeutics for multiple diseases. The pre-proteasomal phase of the pathway, catalyz ...

    SBIR Phase II 2014 Department of Health and Human Services
  8. Novel molecular therapeutics for cystic fibrosis

    Amount: $1,249,853.00

    DESCRIPTION (provided by applicant): Cystic fibrosis (CF) leads to chronic illness, disability, and early death. Recurrent pulmonary infections are lethal owing to growth of bacteria and other microor ...

    SBIR Phase II 2014 Department of Health and Human Services
  9. Identification of natural products to treat neoplastic disease

    Amount: $342,963.00

    DESCRIPTION (provided by applicant): As in the past, most new FDA-approved drugs for cancer and other indications are derived from natural products or inspired by natural products. Accordingly, it is ...

    SBIR Phase I 2012 Department of Health and Human Services
  10. Ubiquitin E3 ligase detection by fluorescence resonance transfer

    Amount: $263,031.00

    DESCRIPTION (provided by applicant): Because of its involvement in a broad range of cellular signal transduction and other mechanisms, the ubiquitin pathway is now recognized as a new opportunity for ...

    SBIR Phase I 2012 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government